Using nanoparticles to deliver chemotherapy targeting specific cancer cells
Official title: Disulfated polyamidosaccharide nanoparticles as a P-selectin targeting chemotherapeutic delivery system
Funded at Boston University (Charles River Campus) · NIH-11071368 · Data updated 2026-11-12
This study is exploring a new way to deliver chemotherapy directly to breast and lung cancer cells in women, using special tiny particles that target a protein found on these cancer cells, with the hope of making treatment more effective and reducing side effects.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2025 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $46,150 |
| NIH project number | 1F31CA298728-01 |
| Project ID | NIH-11071368 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with breast or non-small cell lung cancer, particularly those with specific genetic mutations that may affect treatment response.
✕Less likely to help
Patients with cancers other than breast or lung, or those who do not express high levels of P-selectin, may not benefit from this research.
What this research studies
This research investigates a novel approach to deliver chemotherapy specifically to cancer cells by using disulfated polyamidosaccharide nanoparticles that target P-selectin, a protein found in high levels on certain tumor cells. The study focuses on breast and lung cancers, particularly in women, where metastasis is a significant concern. By enhancing the delivery of chemotherapy directly to these cancer cells, the goal is to improve treatment efficacy and reduce side effects. Patients may benefit from a more targeted treatment option that could potentially lead to better outcomes.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and targeted chemotherapy treatment, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promising results using targeted delivery systems in cancer treatment, indicating that this approach has potential for success.
Where this research is happening
-
Boston University (Charles River Campus)
Boston, United States Active
Researchers
- Principal investigator: Loffredo, Madeline — Boston University (Charles River Campus)
- Study coordinator: Loffredo, Madeline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.